TM2D1

Across TCGA pan-cancer cohorts, TM2D1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TM2D1 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher TM2D1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TM2D1 expression acts as an unfavorable survival marker, although some lineages such as SCLC show a favorable association.

GBM, BLCA, and SCLC are the cancer types where TM2D1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.109	0.415	.032	6	view →
BLCA	DFS	Median	III,IV	0.200	0.574	.042	3	view →
SCLC	DFS	Median	All	1.000	0.269	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TM2D1–GBM (OS)

Open the GBM breakdown →